Sellas Targets Tambiciclib To Adverse-Risk Frontline AML Patients After Phase II Success

 
• By Alaric DeArment
  
Concept of blood cells count, medicine and healthcare. 3d rendering mock up
(Shutterstock)

More from Clinical Trials

More from R&D